Research Details

DSIP Delta Sleep-Inducing Peptide / Emideltide Scientific Research Overview Delta sleep-inducing peptide, also called DSIP or emideltide, is a nine-amino-acid peptide originally isolated during sleep-related research. It has been investigated in relation to sleep architecture, insomnia, stress adaptation, pain signaling, neuroendocrine regulation, and withdrawal-related symptoms. Much of the published human research is several decades old and consists of small exploratory studies. Published Research Findings A double-blind matched-pairs study involving 16 patients with chronic insomnia investigated DSIP’s effects on objective and subjective sleep measurements. The researchers reported sleep-related changes in some participants, but the small sample and variability of responses limited firm conclusions. Earlier human studies involving healthy volunteers and patients with disturbed sleep also reported possible changes in sleep quality, sleep efficiency, and daytime behavior. The results were not consistently reproduced across all participants or study designs, and the evidence base never developed into a large modern clinical program. The historical findings support continued scientific interest in DSIP-related signaling, but they do not establish DSIP as a proven sleep treatment. Evidence and Regulatory Context DSIP is not an FDA-approved drug. In 2026, FDA reviewed emideltide-related bulk substances for proposed uses including chronic insomnia, narcolepsy, and opioid withdrawal. FDA reported that it lacked sufficient safety information for the proposed routes and proposed that emideltide not be included on the Section 503A Bulks List. Advisory review does not itself constitute final drug approval or establish clinical effectiveness. Research Links Double-Blind Study of DSIP in Chronic Insomnia DSIP and Disturbed Human Sleep DSIP in Severe Chronic Insomnia FDA 2026 PCAC Meeting Materials FDA Information Concerning Emideltide Safety Data Research Context: Published findings summarized on this page consist primarily of small, older exploratory studies and limited human observations involving DSIP or emideltide. The evidence does not establish DSIP as an effective treatment for insomnia, narcolepsy, withdrawal, or another medical condition. These findings do not establish the identity, purity, sterility, safety, effectiveness, or regulatory status of the research material offered on this page. This product is sold strictly for lawful laboratory research and is not intended for human or veterinary use.